Triphenyl phosphate (TPHP) is an unsubstituted aryl phosphate ester used as a flame retardant and plasticizer within the United States. Using zebrafish as a model, the objectives of this study were to rely on (1) mRNA-sequencing to uncover pathways disrupted following embryonic TPHP exposure and (2) high-content screening to identify nuclear receptor ligands that enhance or mitigate TPHP-induced cardiotoxicity. Based on mRNA-sequencing, TPHP exposure from 24 to 72-h postfertilization (hpf) resulted in a concentration-dependent increase in the number of transcripts significantly affected at 72 hpf, and pathway analysis revealed that 5 out of 9 nuclear receptor pathways were associated with the retinoid X receptor (RXR). Based on a screen of 74 unique nuclear receptor ligands as well as follow-up experiments, 2 compoundsciglitazone (a peroxisome proliferator-activated receptor gamma, or PPARc, agonist) and fenretinide (a pan-retinoic acid receptor, or RAR, agonist)-reliably mitigated TPHP-induced cardiotoxicity in the absence of effects on TPHP uptake or metabolism. As these data suggested that TPHP may be activating RXR (a heterodimer for both RARs and PPARc), we coexposed embryos to HX 531-a pan-RXR antagonist-from 24 to 72 hpf and, contrary to our hypothesis, found that coexposure to HX 531 significantly enhanced TPHP-induced cardiotoxicity. Using a luciferase reporter assay, we also found that TPHP did not activate nor inhibit chimeric human RXRa, RXRb, or RXRc, suggesting that TPHP does not directly bind nor interact with RXRs. Overall, our data suggest that TPHP may interfere with RXR-dependent pathways involved in cardiac development.
Nuclear receptors play an essential role in development within all vertebrates, acting as transcription factors at highly specific and coordinated stages within developing embryos (Chandler et al., 1983; McKnight and Palmiter, 1979; Polak and Domany, 2006; Rhinn and Doll e, 2012) . In the vertebrate embryo, one of the first organs to form is the heart (Moorman et al., 2003) , a process that is controlled by transcription factors, including homeobox (Schott et al., 1998) , t-box (Basson et al., 1997) , and nuclear receptor proteins (Mendelsohn et al., 1994) . Retinoic acid receptors (RARs) are nuclear receptors necessary for many processes in cardiac development such as cell specification (Wobus et al., 1997) , heart field patterning (Smith et al., 1997) , and myocardial growth (Merki et al., 2005) . RARs can be activated by many structurally different ligands (Blumberg et al., 1996) , but most selectively by all-trans retinoic acid (Giguere et al., 1987) . Upon activation, RARs heterodimerize with retinoid X receptors (RXRs), resulting in binding to retinoic acid response elements and transcription of genes necessary for cardiac development (Minucci et al., 1997) . Optimal activation of RARs is necessary for proper cardiac development and morphogenesis, as excess or insufficient amounts of signaling both lead to cardiotoxicity (Chen et al., 2008; Li et al., 2016) . Therefore, xenobiotics affecting the RAR signaling pathway-either directly or indirectly-can lead to cardiac malformations in developing embryos (Isales et al., 2015; Paganelli et al., 2010) .
Triphenyl phosphate (TPHP) is an unsubstituted aryl phosphate ester flame retardant and plasticizer with an estimated annual production between 10 and 50 million pounds in the United States (Brooke et al., 2009) . TPHP is used in commercial products such as electronic wiring, plasticized vinyl polymers, automotive interiors, and furniture upholstery (van der Veen and de Boer, 2012) . Similar to other additive flame retardants, TPHP can migrate out of end-use products and into indoor dust (Stapleton et al., 2009) . TPHP is also used in nail polish and enamels, and one study demonstrated that, following application of TPHP-containing nail polishes, concentrations of the urinary metabolite of TPHP (diphenyl phosphate, or DPHP) were significantly increased in women (Mendelsohn et al., 2016) . Therefore, humans may be exposed to TPHP via inhalation, ingestion, and/or dermal exposure, although little is known about the potential effects of chronic exposure to human populations, particularly with respect to prenatal development.
Our previous findings demonstrated that TPHP blocks cardiac looping in zebrafish embryos (McGee et al., 2013) . Interestingly, TPHP-induced cardiotoxicity is aryl hydrocarbon receptor-independent (McGee et al., 2013) , and exposure of developing zebrafish to TPHP in the presence of nontoxic concentrations of a pan-RAR antagonist (BMS493) results in enhancement of cardiotoxicity, an effect that is not due to differential uptake or metabolism of TPHP (Isales et al., 2015) . In addition, TPHP is a potent agonist for human peroxisome proliferator-activated receptor gamma (PPARc) within cell lines (Belcher et al., 2014; Pillai et al., 2014) , and induces a significant increase in human PPARc activity at nominal concentrations of >10 lM within cell culture media. As PPARc and RARs are ligand-activated transcription factors that share RXR as a heterodimer (DiRenzo et al., 1997) , activation of PPARc may lead to increased recruitment of available RXR, decreased RAR/RXR heterodimerization, and repressed RAR function. However, little is currently known about how TPHP interferes with pathways regulated by PPARc, RARs, RXRs, and other nuclear receptors, specifically during cardiac development.
Using zebrafish as a model, the overall objective of this study was to identify other potential nuclear receptors involved in mediating TPHP-induced cardiotoxicity during embryonic development. To accomplish this objective, we relied on a combination of mRNA-sequencing, high-content screening, and human reporter assays to test the hypothesis that TPHP interferes with PPARc-and RAR-mediated signaling pathways involved in cardiac development during zebrafish embryogenesis. In addition, we quantified embryonic doses of TPHP and DPHPa primary TPHP metabolite-to confirm that TPHP uptake and metabolism was not affected by coexposure to two nuclear receptor ligands identified from this study.
MATERIALS AND METHODS
Animals. Adult wildtype (strain 5D) zebrafish were maintained on a recirculating system with UV sterilization and mechanical/ biological filtration units (Aquaneering, San Diego, California), and were kept under a 14:10-h light-dark cycle at a water temperature of approximately 27 C-28 C, pH of approximately 7.2, and conductivity of approximately 900-950 lS. Water quality was constantly monitored for pH, temperature, and conductivity using a real-time water quality monitoring and control system. Ammonia, nitrate, nitrite, alkalinity, and hardness levels were manually monitored weekly by test strip (Lifeguard Aquatics, Cerritos, California). Zebrafish were fed once per day with dry diet (Gemma Micro 300, Skretting, Fontaine-lè s-Vervins, France). Adult males and females were bred directly on-system using in-tank breeding traps suspended within 3-l tanks. For all experiments described, newly fertilized eggs were collected within 30 min of spawning, rinsed, and reared in a temperature-controlled incubator (28 C) under a 14:10-h light-dark cycle. All embryos were sorted and staged according to previously described methods (Kimmel et al., 1995 At 72 hpf, embryos were removed from the incubator and anesthetized with 100 mg/l MS-222 by adding 25 ll of 300 mg/l MS-222 to 50 ll of vehicle or treatment solution at 72 hpf. To help orient hatched embryos in right or left lateral recumbency, the plate was centrifuged at 200 rpm for 3 min. Using automated image acquisition protocols and parameters previously optimized (Yozzo et al., 2013) ) were quantified using previously described protocols (Yozzo et al., 2013) . Each well was inspected after imaging to assess embryo orientation and survival. Percent survival and hatch for each treatment group were recorded. Embryos that did not survive or hatch, as well as embryos that were grossly malformed, were not included in the analysis for body length and pericardial area. Using these criteria only hatched and live embryos positioned in right or left lateral recumbency were analyzed.
Prior to conducting the nuclear receptor ligand library screen, we first conducted a range-finding exposure to identify a TPHP concentration that reliably blocked cardiac looping in the absence of effects on hatch rate and survival. A 50 mM stock of TPHP was prepared in 100% DMSO and then serially diluted by 1.25Â to create 5. 4, 6.7, 8.4, 10.5, 13.1, 16.4, 20.5, 25.6, 32 , and 40 mM solutions. These solutions were spiked into embryo media, resulting in 1000-fold dilutions for each treatment group. Each treatment group consisted of 32 embryos exposed to either 0.2% DMSO or TPHP (5.4, 6.7, 8.4, 10.5, 13.1, 16.4, 20.5, 25.6, 32, 40,  or 50 mM) from 24 to 72 hpf. At 72 hpf, embryos were anesthetized and imaged as described earlier. Based on this rangefinding exposure, 20 mM TPHP was selected as a concentration that reliably blocked cardiac looping in the absence of effects on hatch rate and survival. mRNA sequencing. To assess the potential effects of TPHP on the embryonic transcriptome at 72 hpf, 24-hpf embryos (30 embryos per petri dish; 6 petri dishes per treatment) were arrayed in clear petri dishes containing 10 ml of vehicle (0.2% DMSO) or TPHP (5, 10, or 20 mM). Embryos were incubated from 24 to 72 hpf at 28 C under a 14:10-h light-dark cycle and static conditions, snap-frozen in liquid nitrogen at 72 hpf, and stored at À80 C until RNA extraction. After combining 2 replicate petri dishes per pool, 3 replicate pools of up to 60 72-hpf hatched embryos per pool were homogenized in 2-ml cryovials using a PowerGen Homogenizer (Thermo Fisher Scientific, Waltham, Massachusetts), resulting in a total of 12 samples. Following homogenization, a SV Total RNA Isolation System (Promega, Madison, Wisconsin) was used to extract total RNA from each replicate sample per manufacturer's instructions. Libraries were prepared using a QuantSeq 3' mRNA-Seq Library Prep Kit FWD (Lexogen, Vienna, Austria) and indexed by treatment replicate per manufacturer's instructions. Library quality and quantity were confirmed using a Qubit 2.0 Fluorometer and 2100 Bioanalyzer system, respectively. Libraries were then pooled, diluted to a concentration of 1.3 pM (with 1% PhiX control), and single-read (1X75) sequenced on our Illumina MiniSeq Sequencing System (San Diego, California) using a 75-cycle High-Output Reagent Kit. All sequencing data were uploaded to Illumina's BaseSpace in real-time for downstream analysis of quality control. Raw Illumina (fastq.gz) sequencing files (12 files totaling 1.14 GB) are available via NCBI's BioProject database under BioProject ID PRJNA416833, and a summary of sequencing run metrics are provided in Supplementary Table 1 (>90.3% of reads were !Q30). All 12 raw and indexed Illumina (fastq.gz) sequencing files were downloaded from BaseSpace, and uploaded to Bluebee's genomics analysis platform (https://www.bluebee.com) to align reads against the current zebrafish genome assembly (GRCz10). After combining treatment replicate files, a DESeq2 application within Bluebee (Lexogen Quantseq DE 1.2) was used to identify significant treatment-related effects on transcript abundance (relative to vehicle controls) based on a false discovery rate (FDR) p-adjusted value < .01.
Using DESeq2-identified transcripts with a FDR p-adjusted value < .01, downstream analyses were run using Qiagen's Ingenuity Pathway Analysis (IPA) (Germantown, Maryland). Statistically significant transcripts were uploaded to IPA, and human, rat, and mouse homologs were automatically identified within IPA using NCBI's HomoloGene. A Tox Analysis was then performed using a Fisher's Exact Test p-value threshold of .05 as the basis for identifying statistically significant pathways; the algorithm considered both direct and indirect relationships using Ingenuity Knowledge Base (genes only) as the reference set.
Nuclear receptor ligand library screens. All 74 nuclear receptor ligands were first screened in the absence of TPHP for potential effects on survival, hatch, body length, and pericardial area at the limit concentration provided by Enzo within the SCREEN-WELL Nuclear Receptor Ligand Library. Ligand stocks (1 mM for 5 ligands; 10 mM for 69 ligands) were diluted in embryo media, resulting in final treatment concentrations of 1 or 10 mM. For each ligand, 16 embryos were exposed under static conditions from 24 to 72 hpf at 28 C under a 14:10-h light-dark cycle, and then anesthetized and imaged as described earlier. Ligands resulting in <75% survival or hatch, or statistically significant effects on body length and/or pericardial area, were rescreened at 1.25-fold dilutions to identify maximum tolerated concentrations (MTCs) based on survival, hatch, body length, or pericardial area. After identifying the MTC for each ligand, embryos were treated with the MTC of each ligand in the presence or absence of 20 mM TPHP. Each 384-well plate contained a total of 24 treatment groups (1 embryo per well; 1 column per treatment; 16 embryos per treatment): vehicle (0.2% DMSO), 20 mM TPHP, 11 ligands at the MTC, and 11 ligands at the MTC þ 20 mM TPHP. All embryos were treated under static conditions from 24 to 72 hpf at 28 C under a 14:10-h light-dark cycle, and then anesthetized and imaged as described earlier.
Coexposures resulting in a statistically significant increase or decrease in pericardial area relative to 20 mM TPHP alone were repeated at least 3 times to confirm that results were reproducible. If reproducible effects at MTCs were observed at least 2 out of 3 times, ligands were screened in concentration-response format using 3 concentrations per ligand (0.25Â, 0.5Â, or 1Â MTC). Each 384-well plate contained a total of 8 treatment groups (one embryo per well; 1 column per treatment; 16 embryos per treatment): vehicle (0.2% DMSO), 20 mM TPHP, or 3 concentrations per ligand (0.25Â, 0.5Â, or 1Â MTC) in the presence or absence of 20 mM TPHP. All embryos were treated under static conditions from 24 to 72 hpf at 28 C under a 14:10-h light-dark cycle, and then anesthetized and imaged as described earlier.
Coexposures resulting in a concentration-dependent increase or decrease in pericardial area relative to 20 mM TPHP alone were repeated at least twice to confirm that results were reproducible.
Ciglitazone and fenretinide pretreatments. Using clear 96-well assay plates (Corning Incorporated, Corning, New York) containing 2 embryos per well, embryos were pretreated with 300 ml of vehicle (0.2% DMSO), 5.24 mM ciglitazone, or 2.14 mM fenretinide from 24 to 30 hpf as described earlier. At 30 hpf, embryos were transferred to clean, black 384-well microplates with 0.17-mm glassbottom wells containing 50 ml of vehicle (0.2% DMSO) or 20 mM TPHP per well, and then exposed from 30 to 72 hpf as described earlier. This experimental design resulted in 48 embryos per treatment group and 4 different treatment groups per ligand. All 72-hpf embryos were anesthetized and imaged as described earlier.
HX 531 coexposures. Based on results from the library screen, we used a pan-RXR antagonist (HX 531) to determine whether TPHP-induced cardiotoxicity was RXR-dependent. Using identical methods described earlier, the MTC for HX 531 was determined to be 5.24 lM based on static exposure from 24 to 72 hpf. Therefore, we co-exposed embryos to TPHP (5, 10, or 20 lM) in the presence or absence of 2.62 or 5.24 lM HX 531 (0.5Â and 1Â MTC, respectively), and all 72-hpf embryos were anesthetized and imaged as described earlier.
Quantification of embryonic doses of TPHP and DPHP. To ensure that ciglitazone and/or fenretinide were not interfering with embryonic uptake or metabolism of TPHP, we quantified embryonic doses of TPHP and DPHP following co-exposure to ciglitazone or fenretinide in the presence or absence of TPHP. Briefly, 24-hpf embryos (30 embryos per dish; 3 dishes per treatment group) were placed into clear petri dishes containing 10 ml of vehicle (0.2% DMSO), 2.14 lM fenretinide, or 5.24 lM ciglitazone in the presence or absence of 20 lM TPHP. Embryos were incubated as described earlier until 72 hpf. For each replicate pool (3 pools per treatment), 30 72-hpf embryos were placed into a 2-ml cryovial, immediately snap-frozen in liquid nitrogen, and stored at À80 C until analysis. Immediately prior to extraction, samples were spiked with deuterated TPHP (d15-TPHP) and deuterated DPHP (d10-DPHP). Analytes were extracted and quantified similar to previously published methods (Isales et al., 2015) . Tissue extracts were analyzed by LC/MS-MS on an Agilent 1260 Infinity II series LC connected to an Agilent 6460 A triple quadrupole MS detector equipped with an electrospray ionization source. Analytes were separated on a Luna C18 (2)-HST column (50 Â 2 mm; 2.5 lm; Phenomenex, Torrance, California) maintained at 35 C. Method detection limits (MDLs) were defined as 3 times the standard deviation of lab blanks (if present) or 3 times the noise. MDLs for TPHP and DPHP were 0.45 and 0.1 ng, respectively.
Human RXR reporter assays. A cell-based human RXR-driven luciferase reporter assay developed by the Services Group within INDIGO Biosciences (State College, Pennsylvania) was used to determine whether TPHP was an agonist or antagonist of human RXRa-, RXRb-, and/or RXRc. 9-cis-retinoic acid (9-cis-RA) and 3- 6, 7, 5, 8, For each treatment group, spiked culture media (100 ll) was dispensed into triplicate assay wells (using a white 96-well microplate) containing Chinese hamster ovary (CHO) cells stably transfected with (1) expression vector containing the Nterminal GAL4 DNA binding domain fused to the ligand-binding domain of human RXRa-, RXRb-, or RXRc and (2) reporter vector containing a firefly luciferase gene functionally linked to the GAL4-specific upstream activation sequence. Following a 24-h incubation at 37 C under 5% carbon dioxide (CO 2 ), treatment media was discarded and, following 1 rinse with INDIGO's proprietary live cell multiplex buffer, live cell multiplex substrate was added to each well of the assay plate to assess cell viability. Following incubation at 37 C for 30 min, fluorescence was quantified to determine the relative number of live cells per well, and then live cell multiplex substrate was discarded and 100 ll of ONE-Glo Luciferase Assay Reagent (Promega) was added to each well of the assay plate. After a 5-min incubation at room temperature, luminescence was quantified using a GloMax 96 microplate luminometer (Promega). Mean fluorescence and luminescence (6 SD) values were calculated for each treatment group based on triplicate wells per treatment. For cell viability data, mean fluorescence for each treatment group was normalized to mean fluorescence for 9-cis-RA-only wells to determine the percent change in cell viability relative to positive control wells.
Statistical analyses. For exposure, analytical chemistry, and human RXR assay data, a general linear model (GLM) analysis of variance (ANOVA) (a ¼ 0.05) was performed using SPSS Statistics 24, as these data did not meet the equal variance assumption for nonGLM ANOVAs. Treatments groups were compared with vehicle controls using pair-wise Tukey-based multiple comparisons of least square means to identify significant differences in effects.
RESULTS

TPHP Induces Cardiotoxicity Following Initation of Exposure at 24 hpf
Although survival was >85% across all treatment groups, exposure to TPHP from 24 to 72 hpf resulted in (1) a significant, concentration-dependent decrease in percent hatch starting at 25.6 mM TPHP (Supplementary Figure 1A) ; (2) a significant, concentration-dependent decrease in body length starting at 16.4 mM TPHP (Supplementary Figure 1B) ; and (3) a significant, concentration-dependent increase in pericardial area starting at 8.4 mM TPHP (Supplementary Figure 1C) . These data are consistent with our previous results based on exposures from 5 to 72 hpf within 384-well plates (Isales et al., 2015) . Therefore, we selected 20-mM TPHP as an optimal concentration for all coexposures and pretreatment experiments, as this TPHP concentration reliably induced cardiotoxicity based on a 24-to 72-hpf exposure.
mRNA Sequencing Reveals That TPHP Disrupts RXR-Dependent Pathways Raw DESeq2 output for 5, 10, and 20 mM TPHP are provided within Supplementary Tables 2-4, respectively. Based on these data, TPHP exposure from 24 to 72 hpf resulted in a concentration-dependent increase in the total number, magnitude, and statistical significance of affected transcripts at 72 hpf relative to vehicle (0.2% DMSO) controls (Figs. 1A-C for 5, 10, and 20 mM TPHP, respectively). Moreover, there was a concentration-dependent increase in the proportion of significantly decreased transcripts (relative to the total number of significantly affected transcripts), where 0% (0 out of 13), 32% (16 out of 50), and 49% (148 out of 302) of transcripts were decreased following exposure to 5, 10, or 20 mM TPHP, respectively. Based on the lowest p-adjusted value, the most significantly affected transcripts following exposure to 5, 10, or 20 mM TPHP were titincap (tcap), rhodopsin (rho), and MAP kinase interacting serine/threonine kinase 2 b (mknk2b), respectively (Supplementary Tables 2-4) . Curated data available within the Zebrafish Information Network (https://zfin.org/) were then queried to identify wildtype embryonic tissues that normally express transcripts that were significantly impacted in our study. Based on this analysis, we found that 23% (3 out of 13), 20% (10 out of 50), and 12% (36 out of 302) of transcripts following exposure to 5, 10, or 20 mM TPHP, respectively, have been detected within the heart of wildtype embryos (Supplementary Tables 2-4) . Interestingly, tcap, fatty acid-binding protein 1b, tandem duplicate 1 (fabp1b.1), and desmin a (desma)-all 3 of which are expressed within the heartwere significantly increased following exposure to 5 and 10 mM TPHP. Moreover, desma was significantly increased following exposure to all 3 TPHP concentrations, suggesting that this transcript may be a potential indicator of TPHP-induced cardiotoxicity within zebrafish.
Following automated identification of human, rat, or mouse homologs within IPA, 38% (5 out of 13), 50% (25 out of 50), and 58% (175 out of 302) of statistically significant transcripts within embryos exposed to 5, 10, and 20 mM TPHP, respectively, were included in IPA's Tox Analysis; the remaining statistically significant transcripts were excluded by IPA's Tox Analysis due to the absence of human, rat, and/or mouse orthologs within NCBI's Homologene database. A complete list of all significantly affected canonical pathways identified by IPA's Tox Analysis for 5, 10, and 20 mM TPHP are provided within Supplementary Tables 5-7, respectively. Interestingly, based on the remaining transcripts used within IPA, there was a concentration-dependent increase in the number of significantly affected cardiovascular signaling pathways, where 2, 3, and 6 cardiovascular signaling pathways were impacted within embryos exposed to 5, 10, and 20 mM TPHP, respectively (Supplementary Tables 5-7) .
In addition, transcripts linked to a total of 9 nuclear receptor signaling pathways were significantly affected following exposure to 5, 10, and/or 20 mM TPHP ( Figure 1D ). Interestingly, 5 of these 9 nuclear receptor signaling pathways were RXRdependent, and there was a concentration-dependent increase in the number of RXR-dependent pathways affected by TPHP. Although aldosterone signaling in epithelial cells represented a significantly impacted nuclear receptor signaling pathway within embryos exposed to 5 and 20 mM TPHP, this pathway was not significant at 10 mM TPHP due to a lack of significant differences in the abundance of HSPA1L (a heat shock gene)-a transcript that was significantly increased within embryos exposed to 5 and 20 mM TPHP. Tables 8 and 9 ): 4-hydroxyretinoic acid (retinoid metabolite), 9-cis RA (a RXR agonist), 13-cis RA (RAR agonist), 24(S)-hydroxycholesterol (a liver X receptor, or LXR, agonist), acitretin (retinoid), adapalene (RA analog), bisphenol A diglycidyl ether (PPARc antagonist), ciglitazone (PPARc agonist), clofibric acid (PPARa agonist), fenretinide (RAR agonist), geranylgeraniol (farnesoid), LY 171883 (PPARc agonist), pregnenolone (progesterone precursor), TTNPB (RAR agonist), and WY-14643 (PPAR agonist). We screened all 15 ligands in concentration-response format as described earlier, and found that 2 ligands (ciglitazone and fenretinide) reproducibly decreased TPHP-induced cardiotoxicity in a concentrationdependent manner (Figure 3 ; Supplementary Table 10).
Pretreatment With Ciglitazone or Fenretinide Mitigates TPHPInduced Cardiotoxicity
To ensure that ciglitazone and fenretinide were not interfering with embryonic TPHP uptake nor interacting with TPHP in solution, we pretreated embryos with MTCs of ciglitazone or fenretinide (based on survival, hatch, body length, or pericardial area) from 24 to 30 hpf, followed by treatment with 20 mM TPHP alone from 30 to 72 hpf. Based on these experiments, we found that pretreatment with ciglitazone or fenretinide significantly mitigated TPHP-induced cardiotoxicity, although these 2 ligands were unable to block TPHP-induced effects on body length (Figure 4 ).
Coexposure With Ciglitazone or Fenretinide Does Not Affect Embryonic Doses of TPHP or DPHP
Mean embryonic doses of TPHP following a 24-to 72-hpf exposure to vehicle (0.2% DMSO), 5.24 mM ciglitazone, or 2.14 mM fenretinide were below the MDL, whereas mean embryonic doses of TPHP following a 24-to 72-hpf exposure to 20 mM TPHP, 20 mM TPHP þ 5.24 mM ciglitazone, or 20 mM TPHP þ 2.14 mM fenretinide were 3982, 3423, and 4947 ng per 30 embryos, respectively (Supplementary Figure 2) . Mean embryonic doses of DPHP were <29 ng per 30 embryos across all treatments.
Coexposure to a pan-RXR Antagonist (HX 531) From 24 to 72 hpf Enhances TPHP-Induced Cardiotoxicity As RXR antagonists were absent from the SCREEN-WELL Nuclear Receptor Ligand Library and our results with fenretinide (a pan-RAR agonist) and ciglitazone (a PPARc agonist) suggested that TPHP may activate RXR (a heterodimer for both RARs and PPARc), we co-exposed embryos from 24 to 72 hpf to vehicle (0.2% DMSO) or TPHP (5, 10, or 20 mM) in the presence or absence of HX 531 (2.62 or 5.24 mM), a pan-RXR antagonist. However, contrary to our hypothesis, we found that coexposure to 20 mM TPHP and 5.24 mM HX 531 resulted in a significant increase in pericardial area relative to embryos exposed to 20 mM TPHP ( Figure 5 ).
TPHP Is Not an Agonist Nor Antagonist of Human RXRa-, RXRb-, or RXRc Within CHO Cells Although 9-cis-RA was a potent agonist for all 3 human RXRs, TPHP did not activate human RXRs at any of the concentrations tested (up to 50 mM) (Figure 6 ). Similarly, compared with UVI 3003 (a RXR antagonist), exposure to TPHP at all concentrations tested (up to 50 mM) resulted in no effect on 9-cis-RA-induced activation of human RXRa-, RXRb-, or RXRc (Figure 6 ). Cell viability (percent live cells) was >89% across all 3 assays for UVI 3003, 9-cis-RA and TPHP exposures (Supplementary Tables 11 and 12 ). 
DISCUSSION
Although TPHP exposure is ubiquitous and has been detected in urine samples (Ospina et al., 2018) , surface water (Kim et al., 2017) , and indoor environments (Castorina et al., 2017) , little is known about the potential effects of TPHP on early development within humans and wildlife. Within this study, we showed that, similar to initiation of exposure at 5 hpf (approximately 50% epiboly) (Isales et al., 2015) , TPHP disrupted cardiac development following initiation of exposure at 24 hpf (Prim-5), demonstrating that the sensitive window for TPHP exposure in zebrafish was the pharyngula period (24-48 hpf)-a developmental window that includes cardiac looping-and not earlier embryonic stages (<24 hpf) that include differentiation and migration of cardiac progenitor cells. Similar to TPHP, other well-studied environmental chemicals such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Antkiewicz et al., 2005; Henry et al., 1997) and phenanthrene (Zhang et al., 2013) disrupt heart morphogenesis during zebrafish development, resulting in cardiotoxicity during pharyngula. Within zebrafish, initiation of TCDD exposure at either 5 or 24 hpf resulted in a similar magnitude of effect later in development (based on cardiotoxicity and lethality), whereas initiation of TCDD exposure after cardiac formation results in decreased sensitivity and toxicity (Lanham et al., 2012) . Similarly, initiation of exposure to phenanthrene at 6 hpf resulted in a decrease in blood circulation at 36 hpf and increase in pericardial edema at 48 hpf (Incardona et al. 2004) , suggesting that, similar to TCDD, pharyngula represents the sensitive window of exposure for phenanthrene. Similar to these persistent organic compounds, our data support the hypothesis that TPHP interferes with developmental pathways involved in cardiac looping and chamber formation rather than tube heart assembly.
TPHP-induced effects on cardiac tissue were also supported by our mRNA-seq data, as desmin was significantly increased relative to vehicle controls following exposure to all 3 TPHP concentrations. Desmin is a muscle-specific intermediate filament protein that is localized to z-discs within cardiac, skeletal, and smooth muscles (Paulin and Li, 2004) . Importantly, Desmin proteins play a major role in the maintenance and integrity of muscle tissue by forming a 3D scaffold that serves as a bridge from z-discs to other key muscle components (Paulin and Li, 2004) . In zebrafish, desmin is expressed as early as the 1-to 3-somite stage, with maximum expression occurring during Prim-6 (approximately 25 hpf) (Loh et al., 2000) . After expression declines from 25 to 72 hpf, desmin is primarily localized to muscles throughout the developing embryo (Loh et al., 2000) . In zebrafish, morpholino knockdown of desmin leads to decreased sarcomere units, widened and misaligned z-discs, and cardiac defects at 72 hpf, including cardiac edema, disorganized muscle structure, and aberrant cardiac looping (Vogel et al., 2009; Li et al., 2013) . Although overexpression and altered distribution of desmin are observed in human hearts with end-stage congestive heart failure (Heling et al., 2002) , overexpression of desmin in mice display no apparent cardiac deformities nor shortened life spans (Wang et al., 2002) . Therefore, similar to humans, increased levels of desmin at 72 hpf in zebrafish may be an indicator of heart failure following TPHP exposure.
We previously showed that TPHP disrupts RAR-dependent pathways (Isales et al., 2015) , although it is unknown if this interaction is direct or indirect. Therefore, in this study, we relied on IPA to investigate potential nuclear receptor pathways involved in TPHP-induced cardiotoxicity in zebrafish. Interestingly, based on our mRNA-sequencing data, IPA's Tox Analysis revealed that 5 out of 9 nuclear receptor pathways that were significantly impacted were RXR-dependent, suggesting that RXR may be a central mediator of TPHP-induced cardiotoxicity. Other studies have evaluated the role of RXR in cardiac development within vertebrates. For example, exposure of zebrafish embryos to a pan-RXR antagonist (UVI3003) resulted in a wide range of malformations (including cardiac defects) and, similar to our findings with TPHP, pharyngula (24-48 hpf) was the most sensitive window for UVI3003-induced toxicity (Zheng et al., 2015) . Moreover, studies in mice have shown that RARa/RXRa is the predominant heterodimer pair involved in RA-induced myocardial growth and cardiac development (Mascrez et al., 1998) , and that RXRa promotes binding to response elements following RA-induced RARa activation (Mic et al., 2003) . This is contrary to RXR-specific heterodimerization with other nuclear receptors such as PPARs, where RXR may mediate transcription in addition to RXR's heterodimer partners (DiRenzo et al., 1997) . Therefore, the presence of multiple heterodimer partners for RXR, combined with stage-and tissuedependent roles in transcription, underscores the complexity of RXR-dependent signaling and challenges of uncovering 1 or more mechanisms of action for environmentally-relevant chemicals such as TPHP. (A, B) , mean body length (6 SD) (C, D), and mean pericardial area (6 SD) (E, F) of 72-hpf embryos pretreated with vehicle (0.2% DMSO), 5.24 mM ciglitazone, and 2.14 mM fenritinide from 24 to 30 hpf, and then treated with vehicle (0.1% DMSO) or 20 mM TPHP from 30 to 72 hpf. Images were acquired using a 4Â objective and transmitted light within our ImageXpress Micro XLS Widefield High-Content Screening System. Asterisk (*) denotes significant treatment effect (p < .05) relative to vehicle controls (0.2% DMSO), whereas single cross ( †) denotes significant pretreatment effect (p < .05) relative to embryos exposed to 20 mM TPHP alone (n, final number of embryos analyzed per treatment).
Based on results from our nuclear receptor ligand library screen and follow-up experiments, ciglitazone (a PPARc agonist) and fenretinide (RAR agonist) reliably decreased pericardial edema (a biomarker for cardiac looping defects) in a concentration-dependent manner. While we did not assess the affinity of these ligands to zebrafish-specific RARs and PPARc, both compounds are potent RAR and PPARc agonists in human cells (Lee et al., 2012; Pergolizzi et al., 1999) . As PPARc-and RARdependent signaling are necessary for cardiac development (Barak et al., 1999; Li et al., 2016) and pretreatment with either ciglitazone or fenretinide blocked TPHP-induced cardiotoxicity, our findings suggest that TPHP may disrupt normal PPARc-and RAR-dependent signaling required for proper heart development. Moreover, neither embryonic uptake nor metabolism of TPHP was influenced by co-exposure to ciglitazone or fenretinide, demonstrating that ciglitazone and fenretinide uptake interfered with TPHP's mechanism(s) of action responsible for cardiotoxicity during pharyngula (24-48 hpf). Overall, these data suggest that, similar to conclusions from our mRNAsequencing data, TPHP may be interfering with RXR during cardiac looping, as RXR is a heterodimer for both RARs and PPARc.
As these data suggested that TPHP may be activating RXR, we co-exposed embryos to HX 531-a pan-RXR antagonistfrom 24 to 72 hpf and, contrary to our hypothesis, found that coexposure to HX 531 significantly enhanced TPHP-induced cardiotoxicity. These findings support the conclusion that, similar to our findings with BMS493 (a pan-RAR antagonist) (Isales et al. 2015) , TPHP may be acting as an RXR antagonist or indirectly decreasing RXR-dependent signaling. However, within our human RXR reporter assays, we found that TPHP was not an agonist or antagonist of human RXRa-, RXRb-, or RXRc within CHO cells, suggesting that TPHP may not directly bind to RXR within zebrafish. While we did not assess the affinity of HX 531 to zebrafish RXRs (6 genes total: rxraa, rxrab, rxrba, rxrbb, rxrga, and rxrgb) (Waxman and Yelon, 2007) , other studies have confirmed that HX 531 is a potent RXR antagonist in human cells (Ebisawa et al., 1999; Suzuki et al. 2009 ). However, as zebrafish do not possess RARb (Waxman and Yelon, 2007) , there may be differences in ligand-binding specificity and/or disruption of human versus zebrafish RXR signaling following exposure to RXR ligands. Moreover, our human RXR reporter assays only addressed direct interference at the receptor (RXR)-level, whereas our zebrafish assays addressed the potential for TPHP to indirectly interfere with RXR-dependent pathways via direct effects on upstream, RXR-connected pathways. For example, nuclear receptor subfamily 2, group F, member 2 (NR2F2) decreases RAR/RXR signaling by heterodimerizing with RXR (Cooney et al., 1992; Tran et al., 1992) , and is essential for proper cardiac development in mice (Pereira et al., 1999) and vascular development in zebrafish (Swift et al., 2014; Wu et al., 2014) . Therefore, this raises the possibility that, within zebrafish, TPHP may be directly activating NR2F2, resulting in increased NR2F2/RXR heterodimerization and altered RAR/RXR signaling.
In summary, our data collectively suggest that zebrafish nuclear receptors pathways-in particular RXR-dependent pathways-may be involved in mediating TPHP-induced cardiotoxicity. However, we recognize that additional research is needed to (1) determine whether TPHP is a ligand for zebrafish RXRs; (2) confirm that TPHP-induced toxicity in zebrafish embryos is RXR-dependent using genetic approaches that knockdown RXR function; and (3) better characterize TPHP-induced disruption of RXR-mediated signaling networks in vivo. Nevertheless, our current findings continue to highlight the complexity of deciphering mechanisms of developmental toxicity for TPHP in zebrafish and other animal models.
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